Payment overview · 2025
General Payments
$57.79
3 reported records · 3 companies
Healthcare provider profile · identity verified
Daniel Bernard Barnes, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DENVER, NC · NPI 1255372090
Verified facts
What the public records show
CMS Open Payments records show Daniel Bernard Barnes, M.D. received $57.79 in general payments during 2025 across 3 reported records.
Exact Sciences Corporation accounted for 41.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.73 | 41.1% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $20.45 | 35.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.61 | 23.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $57.79 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 476 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 351 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 231 | 91 |
| Losartan Potassium | Losartan Potassium | 214 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 63 |
| Lisinopril | Lisinopril | 184 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 58 |
| Omeprazole | Omeprazole | 134 | 47 |
| Trazodone Hcl | Trazodone Hcl | 129 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 46 |
| Gabapentin | Gabapentin | 106 | 38 |
| Ozempic | Semaglutide | 102 | 22 |
| Metformin Hcl | Metformin Hcl | 92 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 13 |
| Metformin Hcl Er | Metformin Hcl | 84 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 30 |
| Furosemide | Furosemide | 64 | 24 |
| Montelukast Sodium | Montelukast Sodium | 64 | 19 |
| Eliquis | Apixaban | 63 | 22 |
| Ezetimibe | Ezetimibe | 63 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 24 |
| Glipizide Er | Glipizide | 56 | 20 |
| Simvastatin | Simvastatin | 55 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 18 |
| Sertraline Hcl | Sertraline Hcl | 50 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 17 |
| Methylprednisolone | Methylprednisolone | 48 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 14 |
| Meloxicam | Meloxicam | 45 | 18 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 11 |
| Azelastine Hcl | Azelastine Hcl | 38 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 35 |
| Pregabalin | Pregabalin | 38 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | 11 |
| Azithromycin | Azithromycin | 36 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Carvedilol | Carvedilol | 33 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 14 |
| Spironolactone | Spironolactone | 32 | 13 |
| Donepezil Hcl | Donepezil Hcl | 31 | 13 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | 12 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 11 |
| Trulicity | Dulaglutide | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | 17 |
| Famotidine | Famotidine | 20 | 11 |
| Glipizide | Glipizide | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $57.79 · 3 records | Exact Sciences Corporation | APTIMA, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error